Author: admin

  • FIBA Asia Cup 2025 Group Phase: Who's coming out on top? – fiba.basketball

    FIBA Asia Cup 2025 Group Phase: Who's coming out on top? – fiba.basketball

    1. FIBA Asia Cup 2025 Group Phase: Who’s coming out on top?  fiba.basketball
    2. Gilas Pilipinas at 2025 Fiba Asia Cup: where to watch on TV, streaming  Inquirer.net
    3. FanCode acquires exclusive broadcast rights for FIBA Asia Cup 2025  MediaNews4U
    4. India’s basketball coach confident of his team  The Shillong Times
    5. Hashem Abbas the spark as Jordan survive brave India  fiba.basketball

    Continue Reading

  • Palantir Tops $1B Quarterly Revenue; Raises 2025 Outlook

    Palantir Tops $1B Quarterly Revenue; Raises 2025 Outlook

    Palantir (PLTR, Financials) crossed the $1 billion quarterly revenue mark for the first time; lifted its 2025 forecast; and delivered another big win from the AI boom. Adjusted earnings were 16 cents a share; revenue surged 48% to $1 billion; both topped expectations.

    The company now sees full?year revenue of $4.142 billion to $4.150 billion; well above its earlier view. U.S. revenue jumped 68% to $733 million; government sales climbed 53% to $426 million; commercial sales nearly doubled. Contract value swelled 140% to $2.27 billion as Palantir closed 66 deals worth at least $5 million.

    Net income rose 144% to $326.7 million; shares are up more than 100% this year; market value has topped $379 billion.

    This article first appeared on GuruFocus.

    Continue Reading

  • ‘Bridge’ of stray stars reveals active merger of two galaxy clusters

    ‘Bridge’ of stray stars reveals active merger of two galaxy clusters

    The ICL imaged by Englert and his colleagues revealed a special type of galactic merger happening in Abell 3667. Normally, Englert says, mergers that involve the largest galaxy in a cluster, called the brightest cluster galaxy or BCG, occur gradually as it steals stars from many smaller galaxies that surround it. But this new research shows something different happening in this case. Abell 3667 is actually made of two galaxy clusters, each with its own BCG, that are now merging together. The ICL bridge discovered by the researchers suggests that the larger BCG is stealing stars from the smaller one — an event known as a rapid or aggressive merger. As the two BCGs merge, so too do the smaller galaxies that surround them, making Abell 3667 the product of two merging clusters. Data from X-ray and radio frequency observations had suggested a rapid merger in Abell 3667, but this is the first optical evidence to back it up. 

    The appearance of intracluster light in these new images offers a tantalizing preview of what’s to come when the Vera C. Rubin Observatory becomes fully operational later this year or early next. Using a telescope twice the size of Blanco and the largest camera ever built, the Rubin telescope will perform a 10-year scan deep into the entire southern sky, a project called the Legacy Survey of Space and Time.

    “Rubin is going to be able to image ICL in much the same way as we did here, but it’s going to do it for every single local galaxy cluster in the southern sky,” Englert said. “What we did is just a small sliver of what Rubin is going to be able to do. It’s really going to blow the study of the ICL wide open.”

    That will be a scientific bonanza for astronomers and astrophysicists. In addition to revealing the history of galaxy clusters, the ICL holds clues to some of the most fundamental mysteries of the universe, particularly dark matter — the mysterious, invisible stuff thought to account for most of the universe’s mass.

    “ICL is quite important for cosmology,” Dell’Antonio said. “The distribution of this light should mirror the distribution of dark matter, so it provides an indirect way to ‘see’ the dark matter.”

    Seeing the unseeable — that’s a powerful telescope. 

    The Victor M. Blanco Telescope and the Vera C. Rubin Observatory are operated by NOIRLab, the U.S. national center for ground-based, nighttime optical astronomy operated by the National Science Foundation. The research was funded by NSF (AST-2108287), the U.S. Department of Energy (DE-SC-0010010) and the NASA Rhode Island Space Grant Consortium.

    Continue Reading

  • Caterpillar, Eaton results show tariff hit, cast doubt on hottest Wall Street trade

    Caterpillar, Eaton results show tariff hit, cast doubt on hottest Wall Street trade

    Key Points

    • Caterpillar’s operating profit fell 18% compared to the same period last year due to President Donald Trump’s tariffs.
    • Eaton provided third-quarter earnings guidance that missed Wall Street expectations.
    • Caterpillar’s and Eaton’s results cast doubt on the performance of the industrial sector, one of the hottest trades this year.

    Continue Reading

  • Space Genius Unveils New User Interface Packed with Features for Parkers and Operators

    Space Genius Unveils New User Interface Packed with Features for Parkers and Operators

    TAMPA, Fla., Aug. 5, 2025 /PRNewswire/ — Space Genius is proud to unveil a completely redesigned user interface (UI), purpose-built to transform the parking experience from end to end. This powerful update not only simplifies and accelerates the reservation process for parkers, but also empowers operators with expanded branding, messaging, and customization tools. With an intuitive new design and smart feature enhancements, the new UI drives higher engagement, operational efficiency, and a more seamless experience for every user.

    A More Informative and Personalized Experience for Parkers




    The new Space Genius interface offers advanced reporting and powerful tools designed to boost parking lot efficiency and maximize revenue.






    The new Space Genius interface offers advanced reporting and powerful tools designed to boost parking lot efficiency and maximize revenue.

    The new interface was thoughtfully designed to make it easier than ever for customers to navigate, choose, and reserve their parking. Key benefits include:

    • Richer Location Information: Each parking location now features expanded description space and the ability to include photos, helping parkers make more informed decisions.
    • Clearer Location Differentiation: Unique color management options at the location level allow for titles and buttons to stand out, making it easier to distinguish between options.
    • At-a-Glance Details: Shuttle and walking distances from the terminal are now displayed in minutes, giving parkers a clearer sense of travel time.
    • Simplified Cruise Ship Booking: A new reservation widget for the cruise industry condenses the cruise ship selection and sail date process into one seamless screen—making booking faster and easier with fewer clicks.
    • Improved Navigation Post-Booking: Confirmation emails now include Google Maps links, helping users quickly locate their parking spot.
    • Enhanced Communication: Redesigned email templates for confirmation, modification, and cancellation are more visually appealing and fully customizable to match the operator’s brand.

    Stronger Branding and Loyalty Tools for Operators

    The UI update also includes robust tools to help parking operators strengthen their brand presence and customer relationships:

    • Expanded Branding Opportunities: Larger logo placements and increased space for taglines and promotional copy enhance the visual impact of each listing.
    • Increased Loyalty Program Integration: A new sign-up path has been added to confirmation pages, encouraging more customer engagement with loyalty programs.

    “This UI redesign is a big step forward in aligning our technology with the needs of both our parker and operator audiences,” said David Sparks, CMO at Space Genius. “We’ve simplified the booking process while opening up more ways for our partners to brand and connect with their customers.”

    The new UI is now live and will continue to evolve based on user feedback and performance insights.

    About Space Genius
    Space Genius is a leading provider of digital parking reservation and management solutions for the parking industry, offering cutting-edge tools to streamline operations, enhance customer experience, and grow revenue.

    For media inquiries, please contact:
    David Sparks  
    Chief Marketing Officer
    312-933-7683

    SOURCE Space Genius

    Continue Reading

  • Titan sub firm used ‘intimidation tactics’ and ‘critically flawed’ safety practices, US Coast Guard report finds

    Titan sub firm used ‘intimidation tactics’ and ‘critically flawed’ safety practices, US Coast Guard report finds

    Who were the five people on board the Titan?

    The CEO of the submersible company, a British billionaire explorer, a French diver, and a father and son were all on board the Titan submersible that imploded in June 2023.

    Stockton Rush, 61, was the chief executive of OceanGate, the firm which owned the Titan submersible.

    He was an experienced engineer who had previously designed an experimental aircraft and worked on other small submersible vessels.

    British adventurer Hamish Harding, 58, ran Action Aviation, a Dubai-based private jet dealership, and completed several exploration feats.

    He visited the South Pole multiple times – once with former astronaut Buzz Aldrin – and flew into space in 2022 on board Blue Origin’s fifth human-crewed flight.

    Dawood Family/ Lotus Eye Photography/ Reuters

    The CEO of the submersible company, a British billionaire explorer, a French diver and a father and son were all on board the Titan

    British businessman Shahzada Dawood, 48, was from one of Pakistan’s richest families. He was travelling on the sub with his son Suleman, 19, a student at the University of Strathclyde in Glasgow, where he had just completed his first year at the university’s Business School.

    Dawood lived with his wife, Christine, and other child, Alina, in Surbiton, south-west London. The family were spending a month in Canada prior to the dive.

    Also on board was Paul-Henry Nargeolet, 77, a former French Navy diver.

    Nicknamed Mr Titanic, he reportedly spent more time at the wreck than any other explorer and was part of the first expedition to visit it in 1987, just two years after it was found.

    Continue Reading

  • Polycystic ovary syndrome with stroke, hypertension, and cardiovascular diseases: a systematic review and meta-analysis | BMC Women’s Health

    Polycystic ovary syndrome with stroke, hypertension, and cardiovascular diseases: a systematic review and meta-analysis | BMC Women’s Health

  • Dokras A, Luque-Ramírez M, Escobar-Morreale HF. POLYCYSTIC OVARY SYNDROME: ORIGINS AND IMPLICATIONS: Long-term health outcomes in polycystic ovary syndrome. Reproduction. 2025;170(2):e250118. https://doi.org/10.1530/REP-25-0118. PMID: 40555382.

  • Yang H, Xiao ZY, Yin ZH, Yu Z, Liu JJ, Xiao YQ, et al. Efficacy and safety of acupuncture for polycystic ovary syndrome: an overview of systematic reviews. J Integr Med. 2023;21(2):136–48.

    PubMed 

    Google Scholar 

  • Luan YY, Zhang L, Peng YQ, Li YY, Liu RX, Yin CH. Immune regulation in polycystic ovary syndrome. Clin Chim Acta. 2022;531:265–72.

    PubMed 

    Google Scholar 

  • Waghmare SV, Shanoo A. Polycystic ovary syndrome: a literature review with a focus on diagnosis, pathophysiology, and management. Cureus. 2023;15(10):e47408.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Weng L, Zhu Q, Xiang Y, Cao T, Cai J, Liang N, et al. METTL3-mediated m(6)A modification of CD36: Implications for glucose metabolism and inflammatory dysregulation in follicles of polycystic ovary syndrome. Int Immunopharmacol. 2024;143(Pt 1): 113327.

    PubMed 

    Google Scholar 

  • Xu Y, Qiao J. Association of insulin resistance and elevated androgen levels with Polycystic Ovarian Syndrome (PCOS): A Review of Literature. J Healthc Eng. 2022;2022:9240569.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Briceño Silva GD, Thomas Garcia KD, Ajamyan H, Shekhawat P, Rodriguez LC, Hammoud A, et al. Polycystic ovarian syndrome: exploring hypertension and cardiometabolic implications. Cureus. 2024;16(10): e70958.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Mohamed AH, Albasheer O, Ghoniem MA, Abdalghani N, Ayish F, Abdelwahab SI, et al. Impact of lifestyle interventions on reproductive and psychological outcomes in women with polycystic ovary syndrome: a systematic review. Medicine (Baltimore). 2025;104(3): e41178.

    PubMed 

    Google Scholar 

  • Salari N, Nankali A, Ghanbari A, Jafarpour S, Ghasemi H, Dokaneheifard S, et al. Global prevalence of polycystic ovary syndrome in women worldwide: a comprehensive systematic review and meta-analysis. Arch Gynecol Obstet. 2024;310(3):1303–14.

    PubMed 

    Google Scholar 

  • Chiaffarino F, Cipriani S, Dalmartello M, Ricci E, Esposito G, Fedele F, et al. Prevalence of polycystic ovary syndrome in European countries and USA: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022;279:159–70.

    PubMed 

    Google Scholar 

  • Deswal R, Narwal V, Dang A, Pundir CS. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13(4):261–71.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Farhadi-Azar M, Behboudi-Gandevani S, Rahmati M, Mahboobifard F, Khalili Pouya E, Ramezani Tehrani F, et al. The prevalence of polycystic ovary syndrome, its phenotypes and cardio-metabolic features in a community sample of Iranian population: Tehran lipid and glucose study. Front Endocrinol (Lausanne). 2022;13: 825528.

    PubMed 

    Google Scholar 

  • Joham AE, Kakoly NS, Teede HJ, Earnest A. Incidence and predictors of hypertension in a cohort of Australian women with and without polycystic ovary syndrome. J Clin Endocrinol Metab. 2021;106(6):1585–93.

    PubMed 

    Google Scholar 

  • Guzik TJ, Nosalski R, Maffia P, Drummond GR. Immune and inflammatory mechanisms in hypertension. Nat Rev Cardiol. 2024;21(6):396–416.

    PubMed 

    Google Scholar 

  • Charchar FJ, Prestes PR, Mills C, Ching SM, Neupane D, Marques FZ, et al. Lifestyle management of hypertension: International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2024;42(1):23–49.

    PubMed 

    Google Scholar 

  • Goorani S, Zangene S, Imig JD. Hypertension: A Continuing Public Healthcare Issue. Int J Mol Sci. 2024;26(1):123. https://doi.org/10.3390/ijms26010123. PMID: 39795981; PMCID: PMC11720251.

  • Tasić T, Tadić M, Lozić M. Hypertension in women. Front Cardiovasc Med. 2022;9: 905504.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Braekman E, De Bruyne R, Vandekerckhove K, Prytula A. Etiology, risk factors and management of hypertension post liver transplantation. Pediatr Transplant. 2024;28(1): e14630.

    PubMed 

    Google Scholar 

  • Macut D, Mladenović V, Bjekić-Macut J, Livadas S, Stanojlović O, Hrnčić D, et al. Hypertension in polycystic ovary syndrome: novel insights. Curr Hypertens Rev. 2020;16(1):55–60.

    PubMed 

    Google Scholar 

  • Ibrahim S, Bielecki J, Kocabas E, Singh S, Senff JR, Casaubon LK, et al. Lifestyle approaches to hypertension for prevention of stroke and vascular cognitive impairment: a realist review protocol. BMJ Open. 2024;14(9): e088631.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Hilkens NA, Casolla B, Leung TW, de Leeuw FE. Stroke. Lancet. 2024;403(10446):2820–36.

    PubMed 

    Google Scholar 

  • Neil HP. Stroke rehabilitation. Crit Care Nurs Clin North Am. 2023;35(1):95–9.

    PubMed 

    Google Scholar 

  • Tan KS, Pandian JD, Liu L, Toyoda K, Leung TWH, Uchiyama S, et al. Stroke in Asia. Cerebrovasc Dis Extra. 2024;14(1):58–75.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Shafaat O, Sotoudeh H. Stroke Imaging. [Updated 2023 May 1]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK546635/.

  • Qin C, Yang S, Chu YH, Zhang H, Pang XW, Chen L, et al. Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2022;7(1):215.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Pham TTM, Duong TV, Nguyen LTK, Vu MT, Pham KM, Nguyen MH, et al. Association between hypertension and stroke recurrence as modified by pro-oxidant-antioxidant balance: a multi-center study. Nutrients. 2023. https://doi.org/10.3390/nu15102305.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Feigin VL, Brainin M, Norrving B, Martins SO, Pandian J, Lindsay P, et al. World Stroke Organization: global stroke fact sheet 2025. Int J Stroke. 2024;20:17474930241308142.

    Google Scholar 

  • Lalo R, Zekja I, Kamberi F. Association of cardiovascular disease risk and health-related behaviors in stroke patients. Int J Environ Res Public Health. 2023. https://doi.org/10.3390/ijerph20043693.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Cherian T, Morales KF, Mantel CF, Lambach P, Al Awaidy S, Bresee JS, et al. Factors and considerations for establishing and improving seasonal influenza vaccination of health workers: report from a WHO meeting, January 16–17, Berlin, Germany. Vaccine. 2019;37:6255–61.

    PubMed 
    PubMed Central 

    Google Scholar 

  • World Health Organization (WHO). Cardiovascular diseases (2019). 2019. Available from: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1.

  • Olié V, Gabet A, Grave C, Helft G, Fosse-Edorh S, Piffaretti C, et al. Epidemiology of cardiovascular risk factors: non-behavioural risk factors. Arch Cardiovasc Dis. 2024;117(12):761–9.

    PubMed 

    Google Scholar 

  • Orio F, Muscogiuri G, Nese C, Palomba S, Savastano S, Tafuri D, et al. Obesity, type 2 diabetes mellitus and cardiovascular disease risk: an uptodate in the management of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2016;207:214–9.

    PubMed 

    Google Scholar 

  • Özkan S, Yılmaz Ö, Yavuz B. Increased masked hypertension prevalence in patients with polycystic ovary syndrome (PCOS). Clin Exp Hypertens. 2020;42(8):681–4.

    PubMed 

    Google Scholar 

  • Mellembakken JR, Mahmoudan A, Mørkrid L, Sundström-Poromaa I, Morin-Papunen L, Tapanainen JS, et al. Higher blood pressure in normal weight women with PCOS compared to controls. Endocr Connect. 2021;10(2):154–63.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Stewart CE, Sohrabji F. Gonadal hormones and stroke risk: PCOS as a case study. Front Neuroendocrinol. 2020;58: 100853.

    PubMed 

    Google Scholar 

  • Young women with polycystic ovary syndrome have raised risk of heart disease 2020. Available from: https://www.escardio.org/The-ESC/Press-Office/Press-releases/Young-women-with-polycystic-ovary-syndrome-have-raised-risk-of-heart-disease.

  • Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285–92.

    PubMed 

    Google Scholar 

  • Profili NI, Castelli R, Gidaro A, Manetti R, Maioli M, Petrillo M, et al. Possible effect of Polycystic Ovary Syndrome (PCOS) on Cardiovascular Disease (CVD): an update. J Clin Med. 2024;13(3):698.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Guixue G, Yifu P, Xiaofeng T, Qian S, Yuan G, Wen Y, et al. Investigating the causal impact of polycystic ovary syndrome on gestational diabetes mellitus: a two-sample Mendelian randomization study. Front Endocrinol (Lausanne). 2024;15: 1337562.

    PubMed 

    Google Scholar 

  • Zhu T, Cui J, Goodarzi MO. Polycystic ovary syndrome and risk of type 2 diabetes, coronary heart disease, and stroke. Diabetes. 2021;70(2):627–37.

    PubMed 

    Google Scholar 

  • Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, Bidhendi-Yarandi R, Carmina E. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol. 2020;18(1):23.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Douglas CC, Rojo JU. Population and diagnostic characteristics of polycystic ovary syndrome and hyperandrogenism. Womens Health Rep. 2024;5(1):945–53.

    Google Scholar 

  • Zhang S, Darbinian JA, Greenspan LC, Naderi S, Ramalingam ND, Lo JC. Hypertensive blood pressure in adolescent females with polycystic ovary syndrome. Am J Prev Med. 2025;68(2):408–11.

    PubMed 

    Google Scholar 

  • Hayes MG, Urbanek M, Ehrmann DA, Armstrong LL, Lee JY, Sisk R, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun. 2015;6(1):7502.

    PubMed 

    Google Scholar 

  • Joham AE, Ranasinha S, Zoungas S, Moran L, Teede HJ. Gestational diabetes and type 2 diabetes in reproductive-aged women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2014;99(3):E447–52.

    PubMed 

    Google Scholar 

  • Dopler B. Stroke prevention. Dela J Public Health. 2023;9(3):6–10.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Zhou Y, Wang X, Jiang Y, Ma H, Chen L, Lai C, et al. Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: insights from a meta-analysis. Gynecol Endocrinol. 2017;33(12):904–10.

    PubMed 

    Google Scholar 

  • Su J, Fan X, Li M, Yu H, Geng H, Qin Y, et al. Association of lifestyle with reduced stroke risk in 41 314 individuals with diabetes: two prospective cohort studies in China. Diabetes Obes Metab. 2024;26(7):2869–80.

    PubMed 

    Google Scholar 

  • Yonis H, Løkkegaard E, Kragholm K, Granger CB, Møller AL, Mørch LS, et al. Stroke and myocardial infarction with contemporary hormonal contraception: real-world, nationwide, prospective cohort study. BMJ. 2025;388: e082801.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Berni TR, Morgan CL, Rees DA. Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: a population study. J Clin Endocrinol Metab. 2021;106(9):e3369–80.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Barić H, Komljenović S, Bilić K, Migo W, Vitowanu JM, Desnica A, et al. Hematologic indices and chronic subdural hematoma: a single-center cohort study. Asian J Neurosurg. 2024;19(4):735–40.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Dammavalam V, Nolan B, Jain A, Sacknovitz A, Fortunato M, Xu P, et al. Abstract 369: polycystic ovary syndrome as a risk factor for acute ischemic stroke during childbearing years. Stroke Vasc Interv Neurol. 2024;4(S1):e12984_369.

    Google Scholar 

  • Duică F, Dănilă CA, Boboc AE, Antoniadis P, Condrat CE, Onciul S, et al. Impact of increased oxidative stress on cardiovascular diseases in women with polycystic ovary syndrome. Front Endocrinol. 2021;12: 614679.

    Google Scholar 

  • Lo AC, Lo CCW, Oliver-Williams C. Cardiovascular disease risk in women with hyperandrogenism, oligomenorrhea/menstrual irregularity or polycystic ovaries (components of polycystic ovary syndrome): a systematic review and meta-analysis. Eur Heart J Open. 2023;3(4): oead061.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Glintborg D, Rubin KH, Nybo M, Abrahamsen B, Andersen M. Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome. Cardiovasc Diabetol. 2018;17(1):37.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Meun C, Gunning MN, Louwers YV, Peters H, Roos-Hesselink J, Roeters van Lennep J, et al. The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome. Clin Endocrinol. 2020;92(2):150–8.

  • Zhu S, Zhang B, Jiang X, Li Z, Zhao S, Cui L, et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2019;111(1):168–77.

    PubMed 

    Google Scholar 

  • Parveen S, Khan S, Khan MM, Gupta B, Ahmad A, Alam R. Association of lipid profile and obesity in patients with polycystic ovary syndrome. Endocr Regul. 2024;58(1):83–90.

    PubMed 

    Google Scholar 

  • Saei Ghare Naz M, Mousavi M, Firouzi F, Momenan A, Azizi F, Ramezani Tehrani F. Association between insulin resistance indices and liver function parameters among women with polycystic ovary syndrome. Endocrinology, Diabetes & Metabolism. 2024. https://doi.org/10.1002/edm2.490.

  • Liao CC, Chien CH, Yu TS, Li JM. Integrated Chinese and Western medicine for coronary heart disease prevention in polycystic ovary syndrome: a 19-year nationwide cohort study. J Multidiscip Healthc. 2023;16:3959–73.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Juber NF, Abdulle A, Aljunaibi A, Alnaeemi A, Ahmad A, Leinberger-Jabari A, et al. Association between self-reported polycystic ovary syndrome with chronic diseases among emiratis: a cross-sectional analysis from the UAE Healthy Future Study. Int J Womens Health. 2023;15:289–98.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Aghade S, Deshmukh S, Katre D. Assessment of reproductive health, metabolic and cardiovascular risk profile in first-degree relatives of women with polycystic ovarian syndrome: a hospital-based study in Maharashtra, India. Int J Acad Med Pharm. 2023;5(5):682–7.

    Google Scholar 

  • Mahalingaiah S, Li H, Scalise A, Gallagher NJ, Gabra M, Onnela JP, et al. Prevalence of cardiovascular disease among women with a clinician diagnosis of polycystic ovary syndrome in a digital longitudinal cohort. Fertil Steril. 2022;118(4):e190.

    Google Scholar 

  • Forslund M, Landin-Wilhelmsen K, Brännström M, Dahlgren E. No difference in morbidity between perimenopausal women with PCOS with and without previous wedge resection. Eur J Obstet Gynecol Reprod Biol. 2023;285:74–8.

    PubMed 

    Google Scholar 

  • Forslund M, Schmidt J, Brännström M, Landin-Wilhelmsen K, Dahlgren E. Morbidity and mortality in PCOS: a prospective follow-up up to a mean age above 80 years. Eur J Obstet Gynecol Reprod Biol. 2022;271:195–203.

    PubMed 

    Google Scholar 

  • Ryu KJ, Kim MS, Kim HK, Kim YJ, Yi KW, Shin JH, et al. Risk of type 2 diabetes is increased in nonobese women with polycystic ovary syndrome: the National Health Insurance Service-National Sample Cohort Study. Fertil Steril. 2021;115(6):1569–75.

    PubMed 

    Google Scholar 

  • Oliver-Williams C, Vassard D, Pinborg A, Schmidt L. Risk of cardiovascular disease for women with polycystic ovary syndrome: results from a national Danish registry cohort study. Eur J Prev Cardiol. 2021;28(12):E39–41.

    PubMed 

    Google Scholar 

  • Wu CH, Chiu LT, Chang YJ, Lee CI, Lee MS, Lee TH, et al. Hypertension risk in young women with polycystic ovary syndrome: a nationwide population-based cohort study. Front Med. 2020;7:574651.

    Google Scholar 

  • Lee TH, Wu CH, Chen ML, Yip HT, Lee CI, Lee MS, et al. Risk of psoriasis in patients with polycystic ovary syndrome: a national population-based cohort study. J Clin Med. 2020;9(6):1–10.

    Google Scholar 

  • Brouzeng C, Bachelot A, Moriniere C, Vaillant J, Joguet G, Velayoudom FL. Triglycerides as a metabolic target in Afrocaribbean infertile women with polycystic ovary syndrome. Metab Syndr Relat Disord. 2019;17(10):500–4.

    PubMed 

    Google Scholar 

  • Ding DC, Tsai IJ, Wang JH, Lin SZ, Sung FC. Coronary artery disease risk in young women with polycystic ovary syndrome. Oncotarget. 2018;9(9):8756–64.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Ng BK, Lee CL, Lim PS, Othman H, Ismail NAM. Comparison of 25-hydroxyvitamin D and metabolic parameters between women with and without polycystic ovarian syndrome. Horm Mol Biol Clin Invest. 2017;31(3):20160057.

    Google Scholar 

  • Sim SY, Chin SL, Tan JL, Brown SJ, Cussons AJ, Stuckey BG. Polycystic ovary syndrome in type 2 diabetes: does it predict a more severe phenotype? Fertil Steril. 2016;106(5):1258–63.

    PubMed 

    Google Scholar 

  • Rubin KH, Glintborg D, Nybo M, Andersen M, Abrahamsen B. Fracture risk is decreased in women with polycystic ovary syndrome: a register-based and population-based cohort study. J Bone Miner Res. 2016;31(4):709–17.

    PubMed 

    Google Scholar 

  • Merz CNB, Shaw LJ, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, et al. Cardiovascular disease and 10-year mortality in postmenopausal women with clinical features of polycystic ovary syndrome. J Womens Health. 2016;25(9):875–81.

    Google Scholar 

  • Glintborg D, Hass Rubin K, Nybo M, Abrahamsen B, Andersen M. Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol. 2015;172(5):627–38.

    PubMed 

    Google Scholar 

  • Sirmans SM, Parish RC, Blake S, Wang X. Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. J Invest Med. 2014;62(6):868–74.

    Google Scholar 

  • Akbarzadeh M, Moradi F, Dabbaghmanesh MH, Jafari P, Parsanezhad ME. A survey of metabolic syndrome in first-degree relatives (fathers) of patients with polycystic ovarian syndrome. J Endocrinol Metab Diabetes S Afr. 2013;18(2):98–103.

    Google Scholar 

  • Popova PV, Babenko AY, Grineva EN. The prevalence of type 2 diabetes, arterial hypertension and coronary artery disease in perimenopausal women with polycystic ovary syndrome wedge resected in 1972–1989. Diabetes. 2012;61:A649.

    Google Scholar 

  • Iftikhar S, Collazo-Clavell ML, Roger VL, St Sauver J, Brown RD Jr, Cha S, et al. Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med. 2012;70(2):74–80.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Wang ET, Calderon-Margalit R, Cedars MI, Daviglus ML, Merkin SS, Schreiner PJ, et al. Polycystic ovary syndrome and risk for long-term diabetes and dyslipidemia. Obstet Gynecol. 2011;117(1):6–13.

    PubMed 
    PubMed Central 

    Google Scholar 

  • Schmidt J, Landin-Wilhelmsen K, Brännström M, Dahlgren E. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21-year controlled follow-up study. J Clin Endocrinol Metab. 2011;96(12):3794–803.

    PubMed 

    Google Scholar 

  • Moran L, Gibson-Helm M, Teede H, Deeks A. Polycystic ovary syndrome: a biopsychosocial understanding in young women to improve knowledge and treatment options. J Psychosom Obstet Gynecol. 2010;31(1):24–31.

    Google Scholar 

  • Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab. 2006;91(4):1357–63.

    PubMed 

    Google Scholar 

  • Margolin E, Zhornitzki T, Kopernik G, Kogan S, Schattner A, Knobler H. Polycystic ovary syndrome in post-menopausal women – marker of the metabolic syndrome. Maturitas. 2005;50(4):331–6.

    PubMed 

    Google Scholar 

  • Vrbíková J, Cífková R, Jirkovská A, Lánská V, Platilová H, Zamrazil V, et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod. 2003;18(5):980–4.

    PubMed 

    Google Scholar 

  • Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long- term follow-up: a retrospective cohort study. Clin Endocrinol. 2000;52(5):595–600.

    Google Scholar 

  • Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod. 2000;15(4):785–9.

    PubMed 

    Google Scholar 

  • Dahlgren E, Janson PO, Johansson S, Lapidus L, Oden A. Polycystic-ovary-syndrome and risk for myocardial-infarction – evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand. 1992;71(8):599–604.

    PubMed 

    Google Scholar 

  • Ollila MM, Arffman RK, Korhonen E, Morin-Papunen L, Franks S, Junttila J, et al. Women with PCOS have an increased risk for cardiovascular disease regardless of diagnostic criteria-a prospective population-based cohort study. Eur J Endocrinol. 2023;189(1):96–105.

    PubMed 

    Google Scholar 

  • Henney AE, Gillespiec CS, Lai JYM, Schofield P, Riley DR, Caleyachetty R, Barber TM, Miras AD, Dobbie LJ, Hughes DM, Alam U, Hydes TJ, Cuthbertson DJ. Risk of Type 2 Diabetes, MASLD and Cardiovascular Disease in People Living With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2025;110(5):1235–46. https://doi.org/10.1210/clinem/dgae481. PMID: 38986027; PMCID: PMC12012816.

  • Al-Hassany L, Linstra KM, Meun C, van den Berg J, Boersma E, Danser AHJ, et al. Decreased role of neuropeptides in the microvascular function in migraine patients with polycystic ovary syndrome. Atherosclerosis. 2023;384:117172.

    PubMed 

    Google Scholar 

  • Lunde O, Tanbo T. Polycystic ovary syndrome: a follow-up study on diabetes mellitus, cardiovascular disease and malignancy 15–25 years after ovarian wedge resection. Gynecol Endocrinol. 2007;23(12):704–9.

    PubMed 

    Google Scholar 

Continue Reading

  • Samsung creates smarter search for Bixby Voice Assistant – Broadband TV News

    1. Samsung creates smarter search for Bixby Voice Assistant  Broadband TV News
    2. Samsung Redefines AI Search on Smart TVs With a Smarter Bixby Voice Assistant  Samsung Newsroom
    3. From an anti-glare TV to an AI fridge that sees your food: 5 things that struck me at Samsung’s ‘House of Wonder’  NZ Herald
    4. Samsung brings more advanced Bixby to its new TVs  SamMobile
    5. Samsung’s updated Bixby voice assistant for its smart TVs throws its predecessor under the bus  HardwareZone Singapore

    Continue Reading

  • When it comes to finance, ‘normal’ data is actually pretty weird

    When it comes to finance, ‘normal’ data is actually pretty weird

    When business researchers analyze data, they often rely on assumptions to help make sense of what they find. But like anyone else, they can run into a whole lot of trouble if those assumptions turn out to be wrong – which may happen more often than they realize. That’s what we found in a recent study looking at financial data from about a thousand major U.S. companies.

    One of the most common assumptions in data analysis is that the numbers will follow a normal distribution – a central concept in statistics often known as the bell curve. If you’ve ever looked at a chart of people’s heights, you’ve seen this curve: Most people cluster near the middle, with fewer at the extremes. It’s symmetrical and predictable, and it’s often taken for granted in research.

    A one-minute introduction to the concept of the bell curve.

    But what happens when real-world data doesn’t follow that neat curve?

    We are professors who study business, and in our new study we looked at financial data from public U.S. companies – things like firm market value, market share, total assets and similar financial measures and ratios. Researchers often analyze this kind of data to understand how companies work and make decisions.

    We found that these numbers often don’t follow the bell curve. In some cases, we found extreme outliers, such as a few large firms being thousands of times the size of other smaller firms. We also observe distributions that are “right-skewed,” which means that the data is bunched up on the left side of the chart. In other words, the values are on the lower end, but there are a few really high numbers that stretch the average upward. This makes sense, because in many cases financial metrics can only be positive – you won’t find a company with a negative number of employees, for example.

    Why it matters

    If business researchers rely on flawed assumptions, their conclusions – about what drives company value, for example – could be wrong. These mistakes can ripple outward, influencing business decisions, investor strategies or even public policy.

    Take stock returns, for example. If a study assumes those returns are normally distributed, but they’re actually skewed or full of outliers, the results might be distorted. Investors hoping to use that research might be misled.

    Researchers know their work has real-life consequences, which is why they often spend years refining a study, gathering feedback and revising the article before it’s peer-reviewed and prepared for publication. But if they fail to check whether data is normally distributed, they may miss a serious flaw. This can undermine even otherwise well-designed studies.

    In light of this, we’d encourage researchers to ask themselves: Do I understand the statistical methods I’m using? Am I checking my assumptions – or just assuming they’re fine?

    What still isn’t known

    Despite the importance of data assumptions, many studies fail to report tests for normality. As a result, it’s unclear how many findings in finance and accounting research rest on shaky statistical grounds. We need more work to understand how common these problems are, and to encourage best practices in testing and correcting for them.

    While not every researcher needs to be a statistician, everyone using data would be wise to ask: How normal is it, anyway?

    Continue Reading

  • Dementia Diagnosis Takes an Average of 3 Years: New Data

    Dementia Diagnosis Takes an Average of 3 Years: New Data

    TOPLINE:

    The average time to diagnosis (TTD) of dementia was 3.5 years in a new meta-analysis, with younger age at onset and having frontotemporal dementia consistently associated with even longer diagnostic intervals.

    METHODOLOGY:

    • This systematic review and meta-analysis used data from 13 cohort studies published up to December 2024. More than 30,000 patients with a diagnosis of dementia were included, with the age at onset ranging between 54 and 93 years.
    • TTD was defined as the interval between the onset of symptoms, rated by family carers or patients using interviews or medical records, and the final diagnosis.

    TAKEAWAY:

    • A meta-analysis of 10 studies showed the average TTD across all types of dementia was 3.5 years (95% CI, 2.7-4.3), with moderate-quality evidence.
    • An analysis of six studies showed that the average TTD of young-onset dementia was 4.1 years (95% CI, 3.4-4.9), also with moderate-quality evidence.
    • An analysis by dementia type showed consistently longer TTDs for young-onset Alzheimer’s disease (TTD, 4.0 years; 95% CI, 2.7-5.2) and frontotemporal dementia (TTD, 4.7 years; 95% CI, 3.0-6.4).
    • In contrast, TTD in late-onset dementia was 2.9 years (95% CI, 2.6-3.2) in analysis of two studies.

    IN PRACTICE:

    “Timely diagnosis of dementia remains a major global challenge, shaped by a complex set of factors, and specific healthcare strategies are urgently needed to improve it,” lead investigator Vasiliki Orgeta, PhD, Division of Psychiatry, University College London, London, England, said in a press release.

    “Clinician training is critical to improve early recognition and referral, along with access to early intervention and individualized support, so that people with dementia and their families can get the help they need,” Orgeta added.

    SOURCE:

    The study was published online on July 27 in International Journal of Geriatric Psychiatry.

    LIMITATIONS:

    Definitions of TTD varied across studies, with different methods used to assess the first symptoms of dementia. The current meta-analysis did not assess factors affecting TTD. Additionally, individuals with severe dementia may not have accurately remembered when they first experienced symptoms, potentially introducing a recall bias. The findings were also not applicable to low- and medium-income countries.

    DISCLOSURES:

    The investigators reported having no relevant conflicts of interest.

    This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

    Continue Reading